ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2665

Epratuzumab Treatment of Patients with Systemic Lupus Erythematosus and Secondary Sjogren’s Syndrome: An Exploratory Analysis of Phase 3 Studies

Jacques-Eric Gottenberg1, Thomas Dörner2, Hendrika Bootsma3, Valerie Devauchelle-Pensec4, Simon Bowman5, Gordana Kosutic6, Holger Bartz7, Marga Oortgiesen6, Anthony Shock8, Willem Koetse6, Catrinel Galateanu9, Sabine Bongardt7, Xavier Mariette10 and Caroline Gordon11,12, 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Department of Medicine/Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, 3Department of Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, 4Department of Rheumatology and Unit of Immunology, Brest University Medical School, Brest, France, 5Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 6UCB Pharma, Raleigh, NC, 7UCB Pharma, Monheim, Germany, 8UCB Pharma, Slough, United Kingdom, 9UCB Pharma, Brussels, Belgium, 10INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France, 11NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 12Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: B cell targeting, Clinical, Sjogren's syndrome and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Sjögren's Syndrome - Poster II: Clinical Science

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The EMBODY 1 (SL0009; NCT01262365) and EMBODY 2 (SL0010; NCT01261793) phase 3 studies investigated the efficacy and safety of epratuzumab (Emab; Immunomedics Inc), a CD22-targeted monoclonal IgG1 antibody, in patients (pts) with systemic lupus erythematosus (SLE).1 The studies showed no significant difference from placebo (PBO) in any of the primary/secondary outcome measures, although B cell-specific immunological activity and a favourable safety profile were demonstrated. An analysis of the subset of pts with secondary Sjögren’s syndrome (sSjS) is of special interest due to the pathogenic role of B cells in primary SjS.

Methods: In EMBODY 1 & 2, adult pts with moderately to severely active SLE were randomized to PBO or 1 of 2 dosing regimens of Emab (both received a cumulative dose of 2400 mg Emab delivered over the first 4 weeks [wks] of each of four 12-wk treatment cycles), with the primary endpoint measured at Wk 48.1 This post-hoc analysis included pts with an additional diagnosis of sSjS who were SS-A positive at baseline. Biological markers (B cells, IgG/IgM, SS-A), primary/secondary outcome measures of SLE disease activity (BICLA, BILAG, PhGA) and overall safety were assessed.1 For BICLA, missing data were imputed using modified non-responder imputation with p values calculated using logistic regression with factors for treatment, pooled region and baseline disease status. For BILAG and PhGA missing values were imputed using last observation carried forward and p values calculated using ANCOVA adjusted for baseline, region and baseline disease severity.

Results: Across both studies, 170 (11%) SLE pts had sSjS in their medical history; of these, 112 pts (40 PBO, 72 Emab) were SS-A positive at baseline and were included in this analysis. Demographics/disease characteristics did not differ between groups (Table A). A higher proportion of Emab pts achieved a BICLA response at Wks 24 and 48 compared with PBO (Table B). Similarly, reductions from baseline in BILAG total score were numerically greater for Emab than PBO pts at both time points. PhGA did not differ significantly between the two groups; both PBO and Emab pts showed improvements from baseline. During treatment, B cells, IgM, and SS-A decreased in Emab but not PBO pts (Figure, and data not shown); no substantial changes were observed in other parameters including IgG, rheumatoid factor, SS-B. Emab appeared safe and well-tolerated with no difference in the frequency of adverse events from PBO.

Conclusion: In this post-hoc analysis, pts with SLE and sSjS treated with Emab showed improvements in SLE disease activity compared to PBO, with decreases in B cells and B cell-related biomarkers (IgM and SS-A). Further evaluation in a larger SjS population, using SjS-specific outcome measures, is necessary to assess the clinical relevance of the data. References: 1. Clowse MEB, Arthritis Rheumatol. 2015;67


Disclosure: J. E. Gottenberg, None; T. Dörner, Biogen, Bioepis, Pfizer, UCB Pharma, Hospira, Roche, Sanofi, Johnson & Johnson, AbbVie, 5; H. Bootsma, None; V. Devauchelle-Pensec, None; S. Bowman, None; G. Kosutic, UCB Pharma, 3; H. Bartz, UCB Pharma, 3; M. Oortgiesen, UCB Pharma, 3; A. Shock, UCB Pharma, 3; W. Koetse, UCB Pharma, 3; C. Galateanu, UCB Pharma, 3; S. Bongardt, UCB Pharma, 3; X. Mariette, Pfizer Inc, 2,Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, UCB Pharma, 5; C. Gordon, Bristol-Myers Squibb, Merck Serono, UCB Pharma, 5,UCB Pharma, 2.

To cite this abstract in AMA style:

Gottenberg JE, Dörner T, Bootsma H, Devauchelle-Pensec V, Bowman S, Kosutic G, Bartz H, Oortgiesen M, Shock A, Koetse W, Galateanu C, Bongardt S, Mariette X, Gordon C. Epratuzumab Treatment of Patients with Systemic Lupus Erythematosus and Secondary Sjogren’s Syndrome: An Exploratory Analysis of Phase 3 Studies [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/epratuzumab-treatment-of-patients-with-systemic-lupus-erythematosus-and-secondary-sjogrens-syndrome-an-exploratory-analysis-of-phase-3-studies/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epratuzumab-treatment-of-patients-with-systemic-lupus-erythematosus-and-secondary-sjogrens-syndrome-an-exploratory-analysis-of-phase-3-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.